Investor Says BioNTech Misled Shareholders With Predictions Of Vaccine Sales
LOS ANGELES — A biotechnology company misled investors by suggesting that its COVID-19 vaccine was still relevant despite not having approval from the Food and Drug Administration to target the most...To view the full article, register now.
Already a subscriber? Click here to view full article